

GLAXOSMITHKLINE PLC
Form 6-K
February 15, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 15 February 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Conditional Share Awards and Shares withheld or sold to meet tax liabilities

This notification sets out the details of the vesting of awards and the sale or withholding of shares to meet tax liabilities over Ordinary Shares and American Depositary Shares made in 2014 under the GlaxoSmithKline Share Value Plan (SVP), which were conditional on continued employment with the GlaxoSmithKline group. The restricted period for the 2014 SVP awards has now ended and the awards made to Persons Discharging Managerial Responsibility (PDMRs) and a person closely associated with them (PCA) vested on 13 February 2017.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr L Debruyne
 - b) Position/status President, Global Vaccines
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')				
b) Nature of the transaction	ISIN: GB0009252882 The vesting and release of Ordinary Shares awarded in 2014 under the Company's 2009 Share Value Plan.				
c) Price(s) and volume(s)	<table border="0" style="margin-left: 20px;"> <tr> <td style="text-align: right;">Price(s)</td> <td style="text-align: right;">Volume(s)</td> </tr> <tr> <td style="text-align: right;">£15.8281</td> <td style="text-align: right;">6,652</td> </tr> </table>	Price(s)	Volume(s)	£15.8281	6,652
Price(s)	Volume(s)				
£15.8281	6,652				
d) Aggregated information	n/a (single transaction)				
e) Date of the transaction	2017-02-13				
f) Place of the transaction	n/a				
1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mrs V A Whyte
 - b) Position/status Company Secretary
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882
The vesting and release of Ordinary Shares awarded in 2014 under the Company's 2009 Share Value Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.8281	10,050

d) Aggregated information n/a (single transaction)

e) Date of the transaction 2017-02-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs V A Whyte

b) Position/status Company Secretary

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882
The sale of Ordinary Shares to meet tax liabilities further to the vesting and release of the 2014 award under the Company's 2009 Share Value Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.8281	4,725

d) Aggregated information n/a (single transaction)

	Aggregated volume Price	
e)	Date of the transaction	2017-02-13
f)	Place of the transaction	n/a
1. Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr K Slaoui
b)	Position/status	PCA of Dr M M Slaoui (Chairman, Global Vaccines)
c)	Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	GlaxoSmithKline plc American Depositary Shares ('ADSs')
b)	Nature of the transaction	ISIN: US37733W1053 The vesting of ADSs awarded in 2014 under the Company's 2009 Share Value Plan, of which 822 ADSs were withheld to meet tax liabilities.
c)	Price(s) and volume(s)	Price(s) Volume(s) \$40.28 2,300
d) Aggregated information		
d)		n/a (single transaction)
e) Aggregated volume Price		
e)	Date of the transaction	2017-02-13
f)	Place of the transaction	n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: February 15, 2017

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc